PSG In Lab denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for psg in lab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies In-Lab PSG as Experimental

In-laboratory polysomnography is an established, long-standing diagnostic procedure; a denial categorizing it as experimental or investigational is unusual and almost always reflects one of two underlying issues. First, the procedure may have been billed with a code that Aetna's system associates with a newer or less established variant of sleep testing — such as a specific PAP titration protocol, a split-night study variant, or an extended-monitoring add-on — that Aetna's clinical policy has not yet recognized as covered. Second, the denial may be a coding or billing artifact rather than a genuine clinical coverage determination. Clarifying the exact basis for the experimental designation is the first step.

## Why This Denial Is Appealable

Standard attended in-laboratory polysomnography is a foundational diagnostic tool in sleep medicine with a decades-long evidence base and broad professional society endorsement. If Aetna is characterizing the standard procedure as experimental, that characterization is factually contestable. If the denial relates to a specific protocol or add-on, the appeal should address the specific clinical indication for that variant and document why it is within recognized clinical practice for this patient. In either case, the denial is appealable and the supporting documentation is typically straightforward to assemble.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Request the specific clinical policy provision and the procedure code that triggered the experimental designation — this information is essential to structuring the correct appeal.
• External review (ACA §2719): After internal denial, an IRO reviews the medical evidence independently. For a procedure with an established evidence base, external review is often favorable.
• ERISA §503: The plan must disclose the clinical rationale and any guideline relied upon for the experimental determination.
• Expedited review: Available if diagnostic delay creates clinical urgency — document any health risk from delay in writing.
• External review window: Initiate within four months of the final internal denial.

## Documentation to Gather

• Procedure and billing code clarification: Confirm with the billing provider which specific procedure codes were submitted and whether any codes may have been miscoded or submitted with an incorrect modifier.
• Ordering physician's letter: Explanation of why the specific study type ordered is clinically necessary and within recognized clinical practice for this patient's presentation.
• Clinical history: Documentation of symptoms, prior diagnostic workup, and clinical findings supporting the order.
• Applicable professional society guidance: Reference the relevant guideline organization (such as the AASM) generically to situate the procedure within established clinical practice.
• Prior correspondence: Any prior communications with Aetna about coverage of this procedure for this patient.

## Criteria-Mapping Structure

Once the specific policy provision and procedure code issue are identified, obtain Aetna's clinical policy for polysomnography and locate the experimental/investigational criteria. For each criterion, provide the chart evidence and professional society context that demonstrates the procedure is established for this indication. If the issue is a coding artifact, a corrected claim submission may resolve the denial more efficiently than a formal appeal — discuss this with the billing provider before filing.